Imatinib Grindeks (Imatinib)

Imatinib blocks the activity of specific tyrosine kinases—BCR‑ABL, c‑KIT, and PDGFR—by binding to their ATP‑binding sites. This inhibition stops downstream signaling that promotes uncontrolled cell growth and survival, leading to apoptosis of malignant cells that rely on these pathways.

The exact dose of Imatinib is individualized by the prescribing clinician based on the patient’s diagnosis, disease stage, renal and hepatic function, and tolerance. Dosage adjustments are made according to clinical response and any observed adverse effects.

Safety data for imatinib during pregnancy and lactation are limited. The drug is classified as contraindicated or to be used only when the potential benefit outweighs the risk. Women of childbearing potential should discuss contraception and potential risks with their healthcare provider.

To place an order, submit an enquiry on the Imatinib Grindeks product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Imatinib was the first BCR‑ABL tyrosine‑kinase inhibitor and remains a standard first‑line option for CML and GIST. Newer TKIs such as dasatinib or nilotinib may offer faster molecular responses or activity against certain resistant mutations, but they can have different safety profiles and cost considerations.

Imatinib tablets should be stored at ambient temperature below 25 °C, protected from moisture and light. Keep the product in its original blister pack until use, and avoid exposing it to high humidity or extreme temperatures to maintain potency.

Imatinib is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber. Swallow tablets whole; do not crush or chew unless the formulation specifically allows it.

Serious adverse events include hepatotoxicity, cardiotoxicity (such as reduced left‑ventricular ejection fraction), and severe neutropenia or other bone‑marrow suppression. Patients should be monitored regularly for liver enzymes, cardiac function, and complete blood counts to detect these complications early.

Imatinib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking strong CYP3A4 inducers or inhibitors that cannot be managed. Pregnant or breastfeeding women should only use it when the benefit clearly outweighs potential risks.